Detailed price information for Biontech Se ADR (BNTX-Q) from The Globe and Mail including charting and trades.

EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight ...

The publicly traded chapter for CureVac has closed. The biotechnology firm's shares have ceased trading and have been formally delisted from the Nasdaq exchange, marking the final step in its full ...

BioNTech confirmed the successful completion of its public tender offer for CureVac on December 18, 2025, with the acceptance period closing at 0:01 Eastern Time. The all-stock transaction was valued ...

A major regulatory milestone was achieved in November 2025 when Germany’s Federal Cartel Office (Bundeskartellamt) granted clearance for the takeover. BioNTech had initially announced the exchange ...

The PROTAC market is experiencing rapid growth, driven by rising interest in targeted protein degradation as a next-generation therapeutic approach. Expanding oncology pipelines with drugs in clinical ...

Bristol Myers Squibb (NYSE:BMY) executives emphasized “focused execution” in 2025 and pointed to continued momentum entering ...

Brepocitinib 45 mg significantly improved cutaneous sarcoidosis disease activity, achieving a 22.3-point improvement in mean CSAMI-A at Week 16 versus a 0.7-point improvement in placebo (Δ21.6 ...

Brepocitinib 45 mg significantly improved cutaneous sarcoidosis disease activity, achieving a 22.3-point improvement in mean CSAMI-A at Week 16 versus a 0.7-point improvement in placebo (?21.6 PPriova ...